Christoph Westphal to move to Longwood Fund, leaving GSK

Christoph Westphal to move to Longwood Fund, leaving GSK

Dr Christoph Westphal, President of SR One, is to leave GlaxoSmithKline later in 2011 to focus on external business interests, primarily the new venture, Longwood Founders Fund in which GSK is an investor. Dr Westphal will remain an advisor to GSK as Co-chair of the Sirtris Scientific Advisory Board.

Dr Westphal joined GSK in 2008 upon the acquisition of Sirtris, where he was co-founder and CEO. Following the initial successful acquisition and integration of Sirtris, his considerable specialist expertise was leveraged further in GSK, first as leader of GSK's Centre of Excellence for External Drug Discovery (CEEDD) and then onward to head SR One, GSK's venture fund. The role of Sirtris CEO was taken on by Dr. George Vlasuk. The independent Longwood Founders Fund was set up in 2010 with the intention that Dr. Westphal would move to a full time role with Longwood in the future.

Moncef Slaoui, Chairman R&D said, "I would like to recognise Christoph's contributions to GSK and to R&D in the last three years. In addition to his achievements at Sirtris, he has brought an entrepreneur's perspective to our thinking on venture capital investments and deals to help us implement R&D's strategy to diversify through external collaborations. I wish him all the very best at Longwood Founders Fund."

GSK will begin recruitment for a new leader for SR One immediately, and Dr Westphal will leave GSK later this year. The early announcement of Dr Westphal's plans has been made in order to facilitate identification of internal and external candidates to succeed him at SR One.

SR One is GlaxoSmithKline's independent corporate healthcare venture capital fund. SR One invests globally in emerging biotech companies that are focused on drug discovery, development or delivery and have the potential to make products that will have a dramatic benefit to patients. In addition the fund focuses on maximising the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries. The SR One portfolio includes approximately 25 private and public companies, and SR One has invested over $560MM in the biotech space.

Longwood Founders Fund is a healthcare venture capital firm that founds, manages, and builds biotechnology companies. Longwood's mission is to identify technologies and to found companies that will advance new therapeutics that can not only make a difference in the lives of patients worldwide, but also create significant value for investors. This is achieved by leveraging the management team's history of successful biotechnology company formation and operational leadership.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:
UK Media enquiries:
Janet Morgan
(020) 8047 5502
US Media enquiries:
Melinda Stubbee
(919) 483 2839


Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2010.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.